Search results
Results From The WOW.Com Content Network
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
For premium support please call: 800-290-4726 more ways to reach us
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
Finance. Yahoo! Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management. In addition to posting paid partner content from other web sites ...
For premium support please call: 800-290-4726 more ways to reach us
It now expects earnings per share between $2.15 and $2.35. That's up from previous guidance of between $2.05 and $2.25. The company's dividend is $0.42 per share quarterly, or $1.68 annually. It's ...
Click here for in-depth analysis of the latest stock market news and events moving stock prices. Read the latest financial and business news from Yahoo Finance. Show comments. Advertisement ...
Many investors define successful investing as beating the market average over the long term. But the risk of stock...